- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Portable, Full-body CT Scanner Gets FDA Approval
NeuroLogica Corp. has received FDA approval for their portable, full-body, multi-slice CT scanner known as the BodyTom, the company announced this week.
NeuroLogica Corp. has received FDA approval for their portable, full-body, multi-slice CT scanner known as the BodyTom, the company announced this week.
The machine, which the company says is the first of its kind, received 501(k) clearance. The BodyTom is a battery-powered 32-slice CT with an 85 cm gantry and 60cm field of view, and it’s designed to be transported from room to room. It is DICOM 3.1 compliant and compatible with PACS, and other systems, the company said.
“Bringing high resolution imaging technology to the patient rather than moving patients to obtain this kind of vital information for a broad range of applications has to be the future," Dr. Howard Yonas, Chief of Neurosurgery at University of New Mexico Medical Center, said in the company press release. "The ability to bring such a powerful and high quality 32 slice CT scanner into the operating room for intra-operative scanning should have a significant impact on improving care and surgical outcomes.”
The Danvers, Mass.-based company also developed the portable head CT scanner, CereTom. The mobile unit was designed to scan patients suspected of traumatic brain injury and can fit through hospital doorways to perform scans from perfusion imaging to CT angiography.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
